צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Estrella Immunopharma, Inc. (ESLA)

Estrella Immunopharma is collaborating with laboratories and physicians to find ways to combat resistant tumors. The quarterly net income per share growth trend on the GURU.Markets chart demonstrates a pivot driven by alliances with oncology centers for drug launches and the active development of the safe ARTEMIS T-cell therapy. The value of 64.80 shows the latest reading of this metric.
פילוחי נתונים אנליטיים מרוכזים עבור Estrella Immunopharma, Inc. (ESLA)

For Estrella Immunopharma (ESLA), which faces the risk of R&D failure in blood cancer therapy amid a lack of revenue, this indicator serves as a measure of capital management efficiency. By analyzing the history of quarterly EPS changes, an investor assesses the trend of net profit per share, separating real financial stability from speculative noise and determining the probability of future cash flows in a highly competitive environment.